135 related articles for article (PubMed ID: 15862971)
1. Anti-cancer activities of novel D-ring modified 2-substituted estrogen-3-O-sulfamates.
Leese MP; Leblond B; Newman SP; Purohit A; Reed MJ; Potter BV
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):239-51. PubMed ID: 15862971
[TBL] [Abstract][Full Text] [Related]
2. A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
Leese MP; Hejaz HA; Mahon MF; Newman SP; Purohit A; Reed MJ; Potter BV
J Med Chem; 2005 Aug; 48(16):5243-56. PubMed ID: 16078843
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of estrone and estrone-3-O-sulfamate derivatives on mitotic. Arrest, apoptosis, and microtubule assembly in human breast cancer cells.
MacCarthy-Morrogh L; Townsend PA; Purohit A; Hejaz HAM ; Potter BVL ; Reed MJ; Packham G
Cancer Res; 2000 Oct; 60(19):5441-50. PubMed ID: 11034086
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of estrone sulfatase and proliferation of human breast cancer cells by nonsteroidal (p-O-sulfamoyl)-N-alkanoyl tyramines.
Selcer KW; Hegde PV; Li PK
Cancer Res; 1997 Feb; 57(4):702-7. PubMed ID: 9044848
[TBL] [Abstract][Full Text] [Related]
5. Effects of C-17 heterocyclic substituents on the anticancer activity of 2-ethylestra-1,3,5(10)-triene-3-O-sulfamates: synthesis, in vitro evaluation and computational modelling.
Jourdan F; Bubert C; Leese MP; Smith A; Ferrandis E; Regis-Lydi S; Newman SP; Purohit A; Reed MJ; Potter BV
Org Biomol Chem; 2008 Nov; 6(22):4108-19. PubMed ID: 18972041
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological activity of the superestrogen (E)-17-oximino-3-O-sulfamoyl-1,3,5(10)-estratriene: x-ray crystal structure of (E)-17-oximino-3-hydroxy-1,3,5(10)-estratriene.
Hejaz HA; Purohit A; Mahon MF; Reed MJ; Potter BV
J Med Chem; 1999 Aug; 42(16):3188-92. PubMed ID: 10447965
[TBL] [Abstract][Full Text] [Related]
7. The effects of 2-methoxyoestrogen sulphamates on the in vitro and in vivo proliferation of breast cancer cells.
Utsumi T; Leese MP; Chander SK; Gaukroger K; Purohit A; Newman SP; Potter BV; Reed MJ
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):219-27. PubMed ID: 15862969
[TBL] [Abstract][Full Text] [Related]
8. 3,17-disubstituted 2-alkylestra-1,3,5(10)-trien-3-ol derivatives: synthesis, in vitro and in vivo anticancer activity.
Bubert C; Leese MP; Mahon MF; Ferrandis E; Regis-Lydi S; Kasprzyk PG; Newman SP; Ho YT; Purohit A; Reed MJ; Potter BV
J Med Chem; 2007 Sep; 50(18):4431-43. PubMed ID: 17696419
[TBL] [Abstract][Full Text] [Related]
9. 2-phenylindole sulfamates: inhibitors of steroid sulfatase with antiproliferative activity in MCF-7 breast cancer cells.
Walter G; Liebl R; von Angerer E
J Steroid Biochem Mol Biol; 2004 Apr; 88(4-5):409-20. PubMed ID: 15145451
[TBL] [Abstract][Full Text] [Related]
10. 2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity.
Leese MP; Leblond B; Smith A; Newman SP; Di Fiore A; De Simone G; Supuran CT; Purohit A; Reed MJ; Potter BV
J Med Chem; 2006 Dec; 49(26):7683-96. PubMed ID: 17181151
[TBL] [Abstract][Full Text] [Related]
11. 2-Alkylsulfanyl estrogen derivatives: synthesis of a novel class of multi-targeted anti-tumour agents.
Leese MP; Newman SP; Purohit A; Reed MJ; Potter BV
Bioorg Med Chem Lett; 2004 Jun; 14(12):3135-8. PubMed ID: 15149660
[TBL] [Abstract][Full Text] [Related]
12. Non-steroidal and steroidal sulfamates: new drugs for cancer therapy.
Purohit A; Woo LW; Barrow D; Hejaz HA; Nicholson RI; Potter BV; Reed MJ
Mol Cell Endocrinol; 2001 Jan; 171(1-2):129-35. PubMed ID: 11165021
[TBL] [Abstract][Full Text] [Related]
13. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
Laplante Y; Cadot C; Fournier MA; Poirier D
Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17-O,O-bis-sulfamate.
Jourdan F; Leese MP; Dohle W; Hamel E; Ferrandis E; Newman SP; Purohit A; Reed MJ; Potter BV
J Med Chem; 2010 Apr; 53(7):2942-51. PubMed ID: 20225862
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of estrone sulfatase by aromatase inhibitor-based estrogen 3-sulfamates.
Numazawa M; Tominaga T; Watari Y; Tada Y
Steroids; 2006 May; 71(5):371-9. PubMed ID: 16476457
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of analogues of estrone-3-O-sulfamate as potent steroid sulfatase inhibitors.
Lawrence Woo LW; Leblond B; Purohit A; Potter BV
Bioorg Med Chem; 2012 Apr; 20(8):2506-19. PubMed ID: 22455789
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents.
Leese MP; Jourdan FL; Gaukroger K; Mahon MF; Newman SP; Foster PA; Stengel C; Regis-Lydi S; Ferrandis E; Di Fiore A; De Simone G; Supuran CT; Purohit A; Reed MJ; Potter BV
J Med Chem; 2008 Mar; 51(5):1295-308. PubMed ID: 18260615
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, conformational analysis, and biological evaluation of 19-nor-vitamin D3 analogues with A-ring modifications.
Sánchez-Abella L; Fernández S; Verstuyf A; Verlinden L; Gotor V; Ferrero M
J Med Chem; 2009 Oct; 52(19):6158-62. PubMed ID: 19739672
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of deoxyglucose uptake in MCF-7 breast cancer cells by 2-methoxyestrone and 2-methoxyestrone-3-O-sulfamate.
Singh A; Purohit A; Hejaz HA; Potter BV; Reed MJ
Mol Cell Endocrinol; 2000 Feb; 160(1-2):61-6. PubMed ID: 10715539
[TBL] [Abstract][Full Text] [Related]
20. Development of potent non-estrogenic estrone sulfatase inhibitors.
Li PK; Chu GH; Guo JP; Peters A; Selcer KW
Steroids; 1998; 63(7-8):425-32. PubMed ID: 9654650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
